Population pharmacokinetics modeling of levetiracetam in Chinese children with epilepsy

Acta Pharmacologica Sinica

Volumn 33, Issue 6, 2012, Pages 845-851

  Wang, Ying Hui ^a   Wang, Li ^a   Lu, Wei ^b   Shang, De Wei ^b   Wei, Min Ji ^a   Wu, Ye ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Chinese children; epilepsy; levetiracetam; pediatric; population pharmacokinetics

Indexed keywords

ETIRACETAM;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CHINESE; COMPARTMENT MODEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; EPILEPSY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; VALIDATION PROCESS;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; CHINA; EPILEPSY; HUMANS; INFANT; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PIRACETAM;

EID: 84862523622     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.57     Document Type: Article

References (25)

1. Stefan H, Feuerstein TJ. Novel anticonvulsant drugs. Pharmacol Ther 2007; 113: 165-83.
2. Shorvon SD, Lowenthal A, Janz D. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as addon therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 2000; 41: 1179-86.
3. Hwang H, Kim KJ. New antiepileptic drugs in pediatric epilepsy. Brain Dev 2008; 30: 549-55.
4. Stockist A, Lu S, Tonner F. Clinical pharmacology of levetiracetam for the treatment of epilepsy. Expert Rev Pharmacol 2009; 2: 339-50.
5. Zhou B, Zhang Q, Tian L, Xiao J, Stefan H, Zhou D. Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures. Epilepsy Behav 2008; 12: 305-10.
6. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707-24.
7. Fay MA, Sheth RD, Gidal BE. Oral absorption kinetics of levetiracetam: the effect of mixing with food or enteral nutrition formulas. Clin Ther 2005; 27: 594-8.
8. Patsalos PN, Ghattaura S, Ratnaraj N, Sander JW. In situ metabolism of levetiracetam in blood of patients with epilepsy. Epilepsia 2006; 47: 1818-21.
9. Allegaert K, Lewi L, Naulaers G, Lagae L. Levetiracetam pharmacokinetics in neonates at birth. Epilepsia 2006; 47: 1068-9.
10. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007; 48: 1117-22.
11. Toublanc N, Sargentini-Maier ML, Lacroix B, Jacqmin P, Stockis A. Retrospective population pharmacokinetic analysis of levetiracetam in chidren and adolescents with epilepsy. lin Pharmacokinet 2008; 47: 333-41.
12. Pellock JM, Glauser TA, Bebin EM, Fountain NB, Ritter FJ, Coupez RM, et al. Pharmacokinetic study of levetiracetam in children. Epilepsia 2001; 42: 1574-9.
13. Ensom MH, Chang TK, Patel P. Pharmacogenetics: the therapeutic drug monitoring of the future? Clin Pharmacokinet 2001; 40: 783-802.
14. Juenke J, Brown PI, Urry FM, McMillin GA. Drug monitoring and toxicology: A procedure for the monitoring of levetiracetam and zonisamide by HPLC-UV. J Anal Toxicol 2006; 30: 27-30.
15. Lancelin F, Franchon E, Kraoul L. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy. Ther Drug Monit 2007; 29: 576-83.
16. Contin M, Mohamed S, Albani F, Riva R, Baruzzi A. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 873: 129-32.
17. Wang Y, Wei MJ, Wang YX, Wang L. Therapeutic drug monitoring of levetiracetam by HPLC-UV. J Pediatr Pharm 2010; 16: 34-7.
18. Chhun S, Jullien V, Rey E, Dulac O, Chiron C, Pons G. Population pharmacokinetics of levetiracetam and dosing recommendation in children with epilepsy. Epilepsia 2009; 50: 1150-7.
19. Jiang DC, Wang L, Wang YQ, Li L, Lu W, Bai XR. Population pharmacokinetics of valproate in Chinese children with epilepsy. Acta Pharmacol Sin 2007; 28: 1677-84.
20. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther 2007: 82; 17-20.
21. Zhao Q, Jiang J, Li X, Lu ZS, Hu P. Epilepsy Therapy: Study data from Peking Union Medical College, Medical college update knowledge of epilepsy therapy. Pain Central Nerv Sys Week 2007; 5: 83.
22. Pigeolet E, Jacqmin P, Sargentini-Maier ML, Stockis A. Population pharmacokinetics of levetiracetam in Japanese and Western adult. Clin Pharmacokinet 2007; 46: 503-13.
23. Glauser TA, Mitchell WG, Weinstock A, Bebin M, Chen D, Coupez R, et al. Pharmacokinetics of levetiracetam in infants and young children with epilepsy. Epilepsia 2007; 48: 1117-22.
24. Merhar SL, Schibler KR, Sherwin CM, Meinzen-Derr J, Shi J, Balmakund T, et al. Pharmacokinetics of levetiracetam in neonates with seizures. J Pediatr 2011; 159: 152-4.
25. Fountain NB, Conry JA, Rodríguez-Leyva I, Gutierrez-Moctezuma J, Salas E, Coupez R, et al. Prospective assessment of levetiracetam pharmacokinetics during dose escalation in 4- to 12-year-old children with partial-onset seizures on concomitant carbamazepine or valproate. Epilepsy Res 2007; 74: 60-9.